http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2015513083-A
Outgoing Links
Predicate | Object |
---|---|
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N5-10 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1072 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57434 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01T1-161 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
filingDate | 2013-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2015-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | JP-2015513083-A |
titleOfInvention | PSMA elevation identifies fatal prostate cancer |
abstract | Prostate cancer (PC) encompasses various types of tumors including adenocarcinoma and non-adenocarcinoma. Adenocarcinoma and non-adenocarcinoma respond to different treatments and should therefore be treated with different treatments. Even within adenocarcinoma, the lethality of tumors varies significantly from low risk / slow / non-fatal to high risk / lethal. The inability to accurately predict the behavior of individual cancers makes treatment decisions difficult and significantly inappropriate. Increased expression of prostate specific membrane antigen (PSMA) expression is a molecular hallmark of lethal prostate adenocarcinoma. Assessing PSMA expression levels to predict individual cancer behavior would be useful in the diagnosis and treatment of PC. [Selection] Figure 9 |
priorityDate | 2012-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 183.